$MEDP

BURWIG SUSAN E sold $4.5M of MEDP

BURWIG SUSAN E (Exec. VP, Operations) sold 7,500 shares of Medpace Holdings, Inc. (MEDP) at $600.00 ($4.50M total) on 2026-07-28.

Original reporting
SEC EDGAR · BURWIG SUSAN E
Published Jul 29, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MEDP
Neutral
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPNeutralLow
01

Why it matters

The disclosed open-market sale by an executive may influence short-term sentiment, but it does not introduce new company fundamentals or forward-looking guidance.

02

Market read

Traders may monitor MEDP for any clustering of insider activity, but this specific filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether the sale was part of a broader compensation/vesting schedule, tax event, or other non-informational motive; also, it provides no follow-on guidance or performance change.

Relevance 6/10Novelty 4/10Timing: filed after-hours on 2026-07-29, covering a sale dated 2026-07-28

Background

The article is an SEC Form 4 insider transaction for Medpace Holdings, Inc. (MEDP).

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace insider BURWIG SUSAN E, Exec. VP Operations, sold 7,500 shares at $600/share for $4.5M on 2026-07-28 via open-market sale.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction. While the absence of a pre-arranged 10b5-1 plan can attract attention, the article provides no additional company-specific catalyst (earnings, guidance, deal, or regulatory action).

Market effects

Minimal. Insider sale in a single healthcare services name does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs; without additional context, it may not signal business deterioration.

Key entities

  • Medpace Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • BURWIG SUSAN E

    Exec. VP, Operations who sold 7,500 shares at $600/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.